Dual inhibition of FLT3 and AXL by gilteritinib overcomes hematopoietic niche-driven resistance mechanisms in FLT3-ITD acute myeloid leukemia

Dumas, P., Villacreces, A., Guitart, A. V., Ali, E. H., Massara, L., Mansier, O., Bidet, A., Martineau, D., Fernandez, S., Leguay, T., Pigneux, A., Vigon, I., Pasquet, J. and Desplat, V.
Dual inhibition of FLT3 and AXL by gilteritinib overcomes hematopoietic niche-driven resistance mechanisms in FLT3-ITD acute myeloid leukemia.  Clinical Cancer Research. August 16 2021.  doi: 10.1158/1078-0432.ccr-20-3114

Date

BioLife Solutions logo

This website uses cookies to ensure you get the best experience on our website.